Leo Groenewegen
Directeur Général chez NBAB, Nordic BioAnalysis AB
Profil
Leo Groenewegen is currently the Chief Executive Officer at NBAB, Nordic BioAnalysis AB.
Prior to this, he worked as the Chief Financial Officer at NextCell Pharma AB.
Postes actifs de Leo Groenewegen
| Sociétés | Poste | Début |
|---|---|---|
NBAB, Nordic BioAnalysis AB
 NBAB, Nordic BioAnalysis AB BiotechnologyHealth Technology Part of Ilya Pharma AB, NBAB, Nordic BioAnalysis AB engages in bio analytical development, validation and analysis of medicines. The company is based in Södertälje, Sweden. The Swedish company was founded in 2010. The CEO is Leo Groenewegen. NBAB was acquired by Ilya Pharma AB on April 19, 2022. | Directeur Général | 01/09/2022 |
Anciens postes connus de Leo Groenewegen
| Sociétés | Poste | Fin |
|---|---|---|
| NEXTCELL PHARMA AB | Directeur Financier/CFO | - |
Expériences
Fonctions occupées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| NEXTCELL PHARMA AB | Health Technology |
| Entreprise privées | 1 |
|---|---|
NBAB, Nordic BioAnalysis AB
NBAB, Nordic BioAnalysis AB BiotechnologyHealth Technology Part of Ilya Pharma AB, NBAB, Nordic BioAnalysis AB engages in bio analytical development, validation and analysis of medicines. The company is based in Södertälje, Sweden. The Swedish company was founded in 2010. The CEO is Leo Groenewegen. NBAB was acquired by Ilya Pharma AB on April 19, 2022. | Health Technology |